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1  | INTRODUC TION
Individuals with metabolic syndrome and type 2 diabetes (T2D) 
are at high risk of developing age‐related cognitive decline, mild 
cognitive impairment, vascular dementia, and Alzheimer's disease 
(AD) (Baumgart et al., 2015; Duarte, 2015; Frisardi et al., 2010; 
Spauwen, Köhler, Verhey, Stehouwer, & Boxtel, 2013). Indeed, AD 
has been proposed as an insulin resistance‐associated neurodegen‐
erative disorder, with brain alterations that resemble those observed 
in individuals with T2D regarding brain insulin signaling (Steculorum, 
Solas, & Brüning, 2014). Insulin resistance might be directly asso‐
ciated to impaired cortical glucose consumption and cognitive im‐
pairment (Baker et al., 2011), and insulin signaling was proposed to 
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Abstract
Diabetes impacts the central nervous system predisposing to cognitive decline. While 
glucose is the main source of energy fueling the adult brain, brain glycogen is necessary 
for adequate neuronal function, synaptic plasticity and memory. In this study, we tested 
the hypothesis that brain glycogen metabolism is impaired in type 2 diabetes (T2D). 
13C magnetic resonance spectroscopy (MRS) during [1‐13C]glucose i.v. infusion was em‐
ployed to detect 13C incorporation into whole‐brain glycogen in male Goto‐Kakizaki (GK) 
rats, a lean model of T2D, and control Wistar rats. Labeling from [1‐13C]glucose into brain 
glycogen occurred at a rate of 0.25 ± 0.12 and 0.48 ± 0.22 µmol/g/h in GK and Wistar 
rats, respectively (p = 0.028), despite similar brain glycogen concentrations. In addition, 
the appearance of [1‐13C]glucose in the brain was used to evaluate glucose transport and 
consumption. T2D caused a 31% reduction (p = 0.031) of the apparent maximum trans‐
port rate (Tmax) and a tendency for reduced cerebral metabolic rate of glucose (CMRglc; 
−29%, p = 0.062), indicating impaired glucose utilization in T2D. After MRS in vivo, gas 
chromatography‐mass spectrometry was employed to measure regional 13C fractional 
enrichment of glucose and glycogen in the cortex, hippocampus, striatum, and hypothal‐
amus. The diabetes‐induced reduction in glycogen labeling was most prominent in the 
hippocampus and hypothalamus, which are crucial for memory and energy homeostasis, 
respectively. These findings were further supported by changes in the phosphorylation 
rate of glycogen synthase, as analyzed by Western blotting. Altogether, the present re‐
sults indicate that T2D is associated with impaired brain glycogen metabolism.
K E Y W O R D S
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modulate glycogen stores in astrocytes (Muhič, Vardjan, Chowdhury, 
Zorec, & Kreft, 2015). However, little is known on brain glycogen 
metabolism in T2D. Animal models of diabetes characterized by in‐
sulin deficiency and chronic hyperglycemia do not display evident 
alteration of brain glycogen levels (reviewed in Duarte, 2015). On 
the contrary, decreased glycogen content was observed in the cer‐
ebral cortex, hippocampus, and cerebellum of Zucker diabetic fatty 
rats, a model of insulin resistance associated to obesity, as compared 
to lean littermates (Sickmann, Waagepetersen, Schousboe, Benie, & 
Bouman, 2010).
Glucose entering the brain from circulation can be metabolized 
or stored. Glycogen is an endogenous reserve of glucose (in the form 
of dehydrated glucosyl units) that may reach up to 10 µmol/g in the 
rodent brain (Cruz & Dienel, 2002; Duarte, Morgenthaler, & Gruetter, 
2017; Kong et al., 2002; Nelson, Schulz, Passonneau, & Lowry, 1968; 
Swanson, Morton, Sagar, & Sharp, 1992). Although present at an 
order of magnitude lower than liver or skeletal muscle, brain gly‐
cogen can be mobilized rapidly without ATP hydrolysis to support 
cerebral energy metabolism when fuel supply is reduced, such as 
upon hypoglycemia (Choi, Seaquist, & Gruetter, 2003; Duarte et al., 
2017; Herzog et al., 2008) and ischemia (Swanson, Sagar, & Sharp, 
1989). In the mature brain, glycogen is primarily located in astro‐
cytes (Cataldo & Broadwell, 1986). Although glucose from the blood 
stream is calorically sufficient to fuel brain's energetic requirements, 
brain glycogen stores have a prominent physiological role (Bak, 
Walls, Schousboe, & Waagepetersen, 2018). It has been for a long 
time known to be present in astrocytic processes that are adjacent 
to synapses (Koizumi & Shiraishi, 1970; Phelps, 1972). Recent work 
verified that glycogen occupies the finest perisynaptic processes of 
astrocytes (Calì et al., 2016; Oe, Baba, Ashida, Nakamura, & Hirase, 
2016). This glycogen location points toward a special role in the met‐
abolic support to synapses. Indeed, glucose cycling through the as‐
trocytic glycogen pool was proposed to rapidly provide the energy 
for neurotransmitter clearance, which would be necessary upon 
rapid increases of neuronal activity (Shulman, Hyder, & Rothman, 
2001). Indeed, glycogenolysis was found to be necessary for ade‐
quate glutamatergic neurotransmission in vivo (Gibbs, Lloyd, Santa, 
& Hertz, 2007) and in cultured cells (Sickmann, Walls, Schousboe, 
Bouman, & Waagepetersen, 2009). Accordingly, the brain isoform 
of glycogen phosphorylase was reported to be present in a protein 
complex with the most abundant high‐affinity glutamate carrier, 
GLT‐1, which is particularly enriched in small astrocytic processes 
near synapses (Genda et al., 2011). Given that glutamatergic neuro‐
transmission is impaired in T2D (Girault, Sonnay, Gruetter, & Duarte, 
2019, and references there in), it is likely that brain glycogen me‐
tabolism is also perturbed. Moreover, astrocytic glycogen has been 
demonstrated to be necessary for synaptic plasticity, learning and 
memory formation (e.g., Duran, Saez, Gruart, Guinovart, & Delgado‐
García, 2013; Gibbs, Anderson, & Hertz, 2006; Gibbs et al., 2007; 
Newman, Korol, & Gold, 2011; Suzuki et al., 2011).
Goto‐Kakizaki (GK) rats, a non‐obese T2D model that was pro‐
duced by selective breeding of nondiabetic Wistar rats showing 
poor glucose tolerance (Goto, Kakizaki, & Masaki, 1976), are known 
to perform poorly in memory and learning tasks (Duarte et al., 
2019; Li et al., 2013; Xiang et al., 2015). Recently, we reported that 
GK rats display synaptic dysfunction in the hippocampus, impaired 
glutamate‐glutamine cycle rate, and a rearrangement of oxida‐
tive metabolism pathways that fuel brain function (Duarte et al., 
2019; Girault et al., 2019). In the present study, we tested the hy‐
pothesis that brain glycogen metabolism is impaired in insulin‐ 
resistant GK rats. For that, we measured labeling incorporation from 
[1‐13C]glucose into pools of glucose and glycogen in the brain of GK 
and control Wistar rats, as well as brain levels of glycogen metabo‐
lizing enzymes.
2  | METHODS
2.1 | Animals
All procedures were performed in accordance with the Swiss fed‐
eral law on animal experimentation, approved by the local commit‐
tee (EXPANIM‐SCAV), and reported following ARRIVE guidelines. 
Male GK rats (6‐months old, 346 ± 27 g, n = 11) and Wistar rats 
(4–6 months old, 453 ± 71 g, n = 9) from Charles River (L'Arbresle, 
France) were housed in pairs on a 12‐hr light‐dark cycle with lights 
on at 07:00, room temperature at 21–23°C, humidity at 55%–60%, 
and with tap water and food (Kliba Nafag 3436, Provimi‐Kliba, 
Kaiseraugst, Switzerland) provided ad libitum. The present study fo‐
cused on male rats due to major gender differences in the phenotype 
of the GK model (e.g., Desrois et al., 2004, and references therein), 
and because of females’ differential steroid hormone profiles 
have an impact on the brain over the course of diabetes progres‐
sion (Candeias et al., 2016). Based on previously reported vari‐
ances for glycogen turnover in the rat brain (van Heeswijk, Pilloud, 
Morgenthaler, & Gruetter, 2012), we estimated the sample size 
required for a difference between independent means at α = 0.05 
and power 1‐β = 0.9, using G*Power version 3.1.9.2 (Faul, Erdfelder, 
Buchner, & Lang, 2009). Magnetic resonance spectroscopy (MRS) 
experiments were conducted randomly across several weeks (2–3 
experiments per week). Researchers were not blind to the rat strain 
during experiments in vivo. There was blinding to the origin of tissue 
samples during processing.
Significance
The findings of the present study suggest that glycogen 
metabolism is impaired in the brain of insulin‐resistant 
rats, which display synaptic dysfunction and memory im‐
pairment. It is known that brain glycogen is necessary to 
maintain proper glutamatergic neurotransmission, and it is 
important for certain forms of memory. Since insulin resist‐
ance has been proposed in other forms of dementia, such as 
Alzheimer's disease, it is plausible that glycogen metabolism 
is key in mediating actions of insulin in the brain.
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2.2 | MRS experiments in vivo
Eight GK rats and six control rats were fasted overnight and anaes‐
thetized with about 1%–2% isoflurane vaporized in 30% O2 in air. 
Isoflurane level was regulated to maintain respiration at 50–70 breaths 
per minute. Then, catheters were placed into the femoral artery and 
vein as previously detailed (Duarte, Carvalho, Cunha, & Gruetter, 
2009). The venal catheter was used for infusion of [1‐13C]glucose 
(Isotec, Sigma‐Aldrich, Buchs, Switzerland) prepared in phosphate‐
buffered saline (PBS; in mmol/L: 137 NaCl, 2.7 KCl, 1.5 KH2PO4, 8.1 
Na2HPO4, pH 7.4); and the femoral artery catheter served to collect 
blood samples, and to monitor heart rate and arterial blood pressure. 
After surgery, rats were placed in a MR compatible holder, the head 
was stereotaxically fixed, and the radiofrequency coil was placed 
on top of the head. Body temperature was continuously monitored 
with a rectal temperature probe (SA Instruments, Stony Brook, NY, 
USA) and maintained at 37°C with a warm water circulation system. 
Heart rate, blood pressure, and breathing rate were also continuously 
recorded with the SA Instruments monitoring system. Throughout 
the MRS experiment, arterial pH, pressures of CO2 (PaCO2) and O2 
(PaO2), and haematocrit were measured with a Cobas b121 system 
(Roche, Rotkreuz, Switzerland), plasma glucose was measured with 
a Reflotron Plus system (Roche), and plasma lactate with a GM7 
Micro‐Stat analyser (Analox Instruments, London, UK). Additional 
50‐µL plasma samples were collected hourly, and stored at −80°C for 
measurement of insulin concentration (ELISA kit #10‐1250‐01 from 
Mercodia, Uppsala, Sweden), and for MRS analyses in vitro.
Scans in vivo were performed on a 14.1 T/26 cm horizontal 
bore magnet (Magnex Scientific, Abingdon, UK), equipped with 
12‐cm gradients (400 mT/m in 120 μs) and interfaced to a Direct 
Drive console (Agilent Technologies, Palo Alto, CA, USA) using a 
surface coil with a 13C linearly polarized loop and 1H quadrature 
loops. Fast‐spin‐echo images were acquired to visualize anatom‐
ical landmarks for placement of a volume of interest (VOI) with 
420–480 µl in the brain. The static magnetic field was homoge‐
nized by FAST(EST)MAP shimming, and localized 1H MRS using 
STEAM with echo time of 2.8 ms, repetition time of 4 s, and mixing 
time of 20 ms was performed to determine baseline concentration 
of glucose in the brain (Duarte, Lanz, & Gruetter, 2011). 1H spectra 
were analyzed using LCModel (Stephen Provencher Inc., Oakville, 
ON, Canada). Localized 13C MRS was performed with a modified 
SIRENE pulse sequence including 3D outer volume suppression, 
1D inversion nulling, 1D Image‐Selected In vivo Spectroscopy 
(ISIS) module, and bilevel Waltz‐16 nuclear Overhauser effect 
(NOE) and decoupling (van Heeswijk et al., 2012). Spectra were se‐
quentially recorded with 128 scans and repetition time of 1 s for at 
least 9 hr. During 13C MRS, [1‐13C]glucose (1.1 mmol/L) was admin‐
istered as a bolus with 99.9% enrichment, followed by continuous 
infusion with a 70%‐enriched solution (Duarte et al., 2011). Peak 
areas of 13C spectra were quantified by line‐fitting in NUTS (Acorn 
NMR, Livermore, CA USA). Glucose C1 was quantified from each 
recorded spectrum (128 scans), while glycogen C1 was quantified 
from the sum of 32 spectra (4,096 scans), resulting in temporal 
resolutions of 2.1 and 68.3 min, respectively.
2.3 | Brain tissue processing
After 13C MRS, rats were immediately sacrificed with a focused mi‐
crowave fixation device irradiating the brain for 2.3 s at 4 kW and 
2,450 MHz (Gerling Applied Engineering, Modesto, CA, USA). The 
cerebrum was rapidly taken out of the skull and dissected. The hy‐
pothalamus, which was not comprised in the VOI for 13C MRS, was 
dissected and stored. The cortex, hippocampus, and striatum were 
collected from one hemisphere to investigate regional variations of 
glycogen metabolism. The other hemisphere was stored to allow 
scaling the whole‐brain 13C enrichment curves measured in vivo to 
absolute concentration of glucose and glycogen. All samples were 
immediately stored at −80°C until further processing.
Frozen samples were powdered with a mortar and pestle in liq‐
uid N2, homogenized in 30 mmol/L HCl with an ultrasonic homoge‐
nizer Sonopuls HD 2070 with the microtip MS 73 (Bandelin, Berlin, 
Germany), and then boiled for 45 min at 90°C. After adjusting the pH 
to 5 with sodium acetate, samples and standards of glycogen (glyco‐
gen from oyster Type II, Sigma‐Aldrich) were incubated in the pres‐
ence or absence of 30 ng/ml amylo‐α‐1,4‐α‐1,6‐glucosidase (Roche) 
for 2 hr at 37°C (Duarte et al., 2017). After enzymatic digestion, pH 
was adjusted to 7. Samples were then centrifuged at 14,000 g for 
15 min, and supernatants were collected for lyophilization.
2.4 | MRS in vitro
After processing, extracts from the whole hemisphere were lyo‐
philized and then re‐dissolved in 2H2O (99.9% 
2H, Sigma‐Aldrich). 
Plasma samples were diluted 1:20 in 2H2O. After adding sodium fu‐
marate (1.2 µmol) as internal standard, water‐suppressed 1H MRS 
was performed as previously detailed (Duarte, Cunha, & Carvalho, 
2007) on a DRX‐600 spectrometer equipped with a 5‐mm cryo‐
probe (Bruker BioSpin SA, Fallanden, Switzerland). In each sample, 
[12C]glucose was determined from the 1H resonance of α‐glucose 
that consists of a doublet at 5.22 ppm, and [1‐13C]glucose was de‐
termined from the resonances arising from heteronuclear 1H‐13C 
coupling (JHC = 184.5 Hz), which appear as satellites of the central 
α‐glucose H1 doublet at 5.22 ppm.
Concentrations of unlabeled glucose and [1‐13C]glucose were de‐
termined in 1H spectra of non‐digested extracts of the whole hemi‐
sphere. These concentrations were subtracted from those in spectra 
of digested extracts to determine the concentrations of unlabeled 
glycogen and [1‐13C]glycogen in the brain. The concentrations of 
[1‐13C]glucose and [1‐13C]glycogen served to scale 13C labeling 
curves detected in vivo.
2.5 | Analysis of glucose and glycogen metabolism
Glycogen concentrations were reported in terms of glucosyl equiv‐
alents released after amylo‐α‐1,4‐α‐1,6‐glucosidase digestion. 
Absolute concentrations of [1‐13C]glucose and [1‐13C]glycogen in 
the whole‐brain hemisphere were used to scale 13C signal areas 
measured in vivo during the 13C MRS experiment. Plasma glucose 
(Glcplasma) was assumed to be transported into the brain with a 
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reversible Michaelis‐Menten kinetics as previously described for the 
rat brain (Duarte et al., 2011). Therefore, brain glucose (Glcbrain) is 
defined by:
where Tmax is the apparent maximal transport rate, Kt is the appar‐
ent Michaelis constant for glucose transport, CMRglc is the cerebral 
metabolic rate of glucose consumption, and Vd is the physical volume 
for glucose distribution in the brain (0.77 ml/g). Similarly, for [1−13C]
glucose, transport is defined by
As detailed previously (Duarte et al., 2011), Equations 1 and 2 
were fitted to the concentration of [1‐13C]glucose in the brain as a 
function of total glucose and [1‐13C]glucose in plasma, and allowed 
determining Tmax, CMRglc, and Kt.
For the analysis of glycogen metabolism, we assumed that varia‐
tions of glycogen concentration during the experiment are negligible 
(Duarte et al., 2017; Morgenthaler, Koski, Kraftsik, Henry, & Gruetter, 
2006), implying that synthesis and degradation fluxes are equal (Vglyc); 
and that glycolysis does not influence glycogen labeling rate because 
Vglyc«CMRglc (Morgenthaler et al., 2009), and thus labeling of glucose 
resembles that of brain glucose‐6‐phosphate, from which glycogen is 
synthetized. Therefore, the rate of glycogen labeling is given by
This equation was fitted to the curve of [1−13C]glycogen with 
[1‐13C]Glc and Glc obtained using Equations 1 and 2. The turnover 
time of glycogen (τ), i.e., the time required to replace all the glucosyl 
units, is obtained by dividing brain glycogen content by Vglyc.
2.6 | Enzymatic determination of glucose and gas 
chromatography‐mass spectrometry (GC‐MS) analysis
Glucose concentration in processed extracts from the hypothalamus, 
cortex, hippocampus, and striatum was determined by the glucose 
oxidase method coupled to a peroxidase reaction to colorimetrically 
detect H2O2 formation (Duarte et al., 2017). Briefly, samples and glu‐
cose standards were diluted in 50 mmol/L sodium phosphate buffer 
(pH 7.4) and incubated in the presence of 2 U/ml glucose oxidase 
(Sigma‐Aldrich), 0.2 U/ml horseradish peroxidase (Sigma‐Aldrich) and 
100 μmol/L AmplexRed (Invitrogen, Basel, Switzerland) for 30 min 
in the dark. Resorufin, the product of AmplexRed oxidation, was de‐
tected at 560 nm with a PowerWave XS microplate spectrophotometer 
(BioTek, Luzern, Switzerland). Glycogen concentration was reported 
in terms of glucosyl equivalents released after amylo‐α‐1,4‐α‐1,6‐glu‐
cosidase digestion, and normalized to the tissue's wet weight.
Processed extracts from the hypothalamus, cortex, hippocampus, 
and striatum were lyophilized and subsequently derivatized and ana‐
lyzed by GC‐MS to establish 13C‐labeling in glycogen‐derived glucose 
using a method adapted and modified from Jackson, Waterhouse, 
and Bluck (2007). Glucose butylboronate derivatives were prepared 
by adding 100 µl of a 10 mg/ml solution of 1‐butylboronic (Sigmal‐
Aldrich) acid in pyridine (Sigma‐Aldrich) to a maximum of 50 µg of 
12C‐glucose (Sigma‐Aldrich) (standards) or the fully dried extracts con‐
taining a minimum of 1 µg of glucose. Subsequently, the resulting mix‐
tures were whirl‐mixed, spun down, and heated at 80°C for 1 hr. The 
derivatization was completed by the addition of 10 µl of acetic anhy‐
dride (Sigma‐Aldrich) to the cooled pyridine‐mixture, whirl‐mixing, and 
heating at 80°C for 1 hr. The samples were subsequently dried under 
nitrogen at 60°C, and the residue taken up in 100 µl of trimethylpen‐
tane (Sigma‐Aldrich) containing 1% of acetic anhydride for stabiliza‐
tion. The samples were transferred to inserts and run on GC‐MS using 
an Agilent Technologies 7820A chromatograph (Agilent J&W GC col‐
umn HP‐5MS, parts no. 19091S‐433) coupled to Agilent Technologies 
5977E mass spectrometer. Isotopic enrichment was corrected for nat‐
ural abundance of 13C in the standards and natural abundance of 10B in 
the derivatization agent, and calculated according to Biemann (1962) 
and Walls, Bak, Sonnewald, Schousboe, and Waagepetersen (2014).
2.7 | Western blotting
Rats (n = 3 from each strain) were briefly anesthetized with isoflu‐
rane (3.5% in air) before being killed by decapitation. The brain was 
rapidly removed and brain regions dissected in ice‐cold PBS. Tissue 
samples were homogenized with a needle sonicator in lysis buffer 
[in mmol/L: 150 NaCl, 1 ethylenediaminetetraacetic acid (EDTA), 50 
tris(hydroxymethyl)aminomethane (Tris)‐HCl, 1% (v/v) Triton X‐100, 
0.5% (w/v) sodium deoxycholate, 0.5% (w/v) sodium dodecylsul‐
fate (SDS), pH 8.0] containing phosphatase and protease inhibitors 
(Roche, Switzerland). The homogenate was then maintained in con‐
stant agitation for 2 hr at 4°C. After centrifugation at 3,000 g for 
10 min at 4°C to remove major debris, the supernatant was saved. 
Total protein content was determined with the bicinchoninic acid 
assay from Pierce (Thermo Fisher Scientific, Göteborg, Sweden).
Samples were then diluted in sample buffer (in mmol/L: 141 Tris‐
base, 106 Tris‐HCl, 50 dithiothreitol, 0.51 EDTA, 0.22 Coomassie 
Brilliant Blue G‐250, 0.175 Phenol Red; 2% (w/v) lithium do‐
decylsulfate, 10% Glycerol, pH 8.5), 40 or 100 µg of protein were 
loaded in precast NuPAGE Novex 4%–12% polyacrylamide gradi‐
ent gels (Invitrogen, Thermo Fisher Scientific) along with molecular 
weight standards (Precision Plus Protein standards from BioRad, 
Sundbyberg, Sweden), and electrophoresis was carried out at with 
at 125 V in a 3‐(N‐morpholino)propanesulfonic acid (MOPS) running 
buffer (in mmol/L: 50 MOPS, 50 Tris Base, 1 EDTA, 0.1% SDS, pH 7.7).
(1)
dGlcbrain
dt
=Tmax
Glcplasma−
Glcbrain
/
Vd
Glcplasma+
Glcbrain
/
Vd
+Kt
−CMRglc,
(2)
d[1−13C]Glcbrain
dt
= Tmax
[ 1−13C]Glcplasma−
[ 1−13C]Glcbrain
/
Vd
Glcplasma+
Glcbrain
/
Vd
+Kt
−CMRglc
[ 1−13C]Glcbrain
Glcbrain
.
(3)
d[1−13C]Glycogen
dt
=Vglyc
(
[ 1−13C]Glc
Glc
−
[ 1−13C]Glycogen
Glycogen
)
.
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Proteins were transferred onto 0.45 µm polyvinylidene difluo‐
ride membranes (GE Life Sciences, Sweden) in a buffer composed of 
39 mmol/L glycine, 48 mmol/L Tris and 20% (v/v) methanol (pH 9.2). 
The membranes were subsequently blocked for 90 min in 5% (w/v) 
bovine serum albumin solution prepared in Tris‐buffered saline (in 
mmol/L: 50 Tris, 150 NaCl, pH 7.4) with 0.1% (v/v) tween‐20 (TBS‐T), 
and then were incubated with primary antibodies diluted in the block‐
ing solution at 1:1,000 were incubated at 4 ᵒC overnight. Antibodies 
against glycogen synthase (#3886; RRID:AB_2116392; clone 15B1; 
raised in rabbit) and phospho(Ser641)‐glycogen synthase (#3891; 
RRID:AB_2116390; produced in rabbit) were purchased from Cell 
Signaling (Leiden, The Netherlands). Antibodies against glycogen 
phosphatase brain and muscle isoforms (produced in chicken and 
guinea pig, respectively) were developed and characterized by the 
Metabolic Engineering and Diabetes Therapy Lab (Duran et al., 
2013; Sinadinos et al., 2014) and kindly provided by Jordi Duran (IRB 
Barcelona, Spain). Rabbit antiserum against the C‐terminal region of 
glucose transporter 1 (GLUT1; Holman et al., 1990) was kindly pro‐
vided by Samuel W. Cushman (National Institutes of Health, USA). 
After three washes in TBS‐T containing 1% BSA, membranes were 
incubated with the respective horseradish peroxidase‐conjugated 
antibodies: goat anti‐rabbit IgG (#ab6721, AbCam, Cambridge, 
UK; RRID:AB_955447), rabbit anti‐chicken IgG (#AP162P, Merck‐
Millipore, Darmstadt, Germany; RRID:AB_11212232), or goat anti‐
guinea pig IgG (#AP108P, Merck‐Millipore; RRID:AB_11211870) for 
1h at room temperature. After three more washes, the membranes 
were developed in the ChemiDoc (BioRad) using the SuperSignal 
West Pico PLUS Chemiluminiscent substrate (Thermo Scientific). All 
membranes were then re‐probed for β‐actin (clone AC15, produced 
in mouse; #ab6276, AbCam; RRID:AB_2223210; secondary anti‐
body was goat anti‐mouse IgG, #ab6789, AbCam; RRID:AB_955439) 
to confirm that similar protein content was loaded in each gel lane.
2.8 | Statistics
Statistical analyses were performed using Prism 8.0.1 (GraphPad, 
San Diego, California, USA). Results are shown as mean ± SD. Data 
were assumed to follow normality, linearity, and equality of variance. 
Significant differences between GK and Wistar rat groups were con‐
sidered for p < 0.05 on Student t tests. Two‐way ANOVA was applied 
to compare glycogen and glucose concentrations and labeling origi‐
nating from multiple brain areas, and the Holm‐Sidak's test was used 
for post hoc multiple comparisons.
3  | RESULTS
3.1 | Glycogen metabolism
Baseline plasma glucose measured before MRS was 10.4 ± 1.2 mmol/L 
in GK rats and 5.5 ± 0.9 mmol/L in controls (p < 0.001). Brain glucose 
content measured by 1H MRS in vivo before [1‐13C]glucose infusion, 
was 1.4 ± 0.5 µmol/g in GK rats and 0.8 ± 0.4 µmol/g in Wistar rats 
(p = 0.006).
Animals were maintained on free breathing, and GK rats re‐
quired lower mean isoflurane levels than Wistar rats (1.0 ± 0.1% vs. 
1.4 ± 0.1%, p < 0.001) to achieve similar respiration rates (Table 1). 
Although physiology parameters were maintained within the nor‐
mal range across the whole experimental protocol under isoflurane 
anesthesia, there were some differences between the two groups 
(Table 1). Namely, relative to controls, GK rats displayed significantly 
lower PaCO2 (−11%, p = 0.031). Given their insulin resistance, GK rats 
required slower glucose infusion rate than controls to achieve simi‐
lar glycaemia (−43%, p = 0.004). Since less [1‐13C]glucose solution is 
administered, GK rats displayed slightly larger hematocrit than con‐
trols (+9%, p = 0.024) without changes in total hemoglobin content. 
Moreover, consistent with the slower glucose disposal rate, GK rats 
had lower circulating lactate levels than controls (−61%, p < 0.001). 
Insulin concentration in circulation increased upon glucose adminis‐
tration, and was similar in GK and Wistar rats.
In Wistar rats, the fractional enrichment (FE) of plasma glucose 
was stable throughout the infusion protocol, reaching 0.61 ± 0.05 
at the end of the 13C experiment (Figure 1b). On the contrary, the 
FE of plasma glucose in GK was below that of Wistar, and reached 
0.46 ± 0.06 at the end (p < 0.001 vs. Wistar). In agreement, FE of 
glucose in the brain extracts was also lower in GK when compared 
to Wistar rats (0.42 ± 0.09 vs. 0.57 ± 0.06, p < 0.003).
TA B L E  1   Mean physiology parameters across the MRS protocol
 Wistar (n = 6) GK (n = 8) p values
Temperature (°C) 37.4 ± 0.2 37.6 ± 0.6 0.451
Respiration rate 
(breaths/minute)
64 ± 7 58 ± 3 0.072
Heart rate (beats/
minute)
406 ± 37 352 ± 88 0.185
Blood pressure (mm Hg)
Systole 162 ± 56 166 ± 62 0.901
Dyastole 103 ± 61 100 ± 79 0.887
Saturation O2 (%) 95.5 ± 2.4 96.5 ± 4.0 0.600
Total hemoglobin 
(g/dl)
14.8 ± 1.2 15.0 ± 0.8 0.772
Hematocrit (%) 34.6 ± 2.2 37.6 ± 2.3 0.024
pH 7.36 ± 0.02 7.39 ± 0.03 0.069
PaCO2 (mm Hg) 41.2 ± 3.7 36.8 ± 2.8 0.031
PaO2 (mm Hg) 187 ± 49 221 ± 99 0.457
HCO3
‐ (mmol/L) 22.7 ± 1.0 21.6 ± 1.7 0.123
Insulin concentration (µg/L)
Baseline 0.24 ± 0.20 0.23 ± 0.05 0.942
During infusion 1.76 ± 1.40 1.69 ± 1.12 0.917
Lactate concentration (mmol/L)
Baseline 0.94 ± 0.22 0.91 ± 0.34 0.840
During infusion 3.15 ± 0.51 1.24 ± 0.31 <0.001
Glucose disposal 
rate (g/kg/h)
1.42 ± 0.32 0.81 ± 0.34 0.004
p values result from comparisons using two‐tailed Student t tests.
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At the end of the glucose infusion protocol, whole‐brain glucose 
concentration (determined in tissue extracts), was 4.4 ± 0.8 µmol/g 
in GK rats and 4.2 ± 1.6 µmol/g in Wistar rats (p = 0.794). Whole‐
brain glycogen concentration was also similar in the two groups: 
5.0 ± 1.1 µmol/g in GK rats and 5.5 ± 2.3 µmol/g in Wistar rats 
(p = 0.681). Like for labeling of plasma and brain glucose, brain glyco‐
gen FE was lower in GK than Wistar rats (0.14 ± 0.02 vs. 0.24 ± 0.07, 
p = 0.004).
The labeling of brain [1‐13C]glucose and [1‐13C]glycogen was de‐
tected in real time by 13C MRS (Figure 2). Glucose 13C signals from α 
and β anomeres were quantified in each spectrum (128 scans), that 
is at a temporal resolution of about 2 min. In contrast, given the slow 
turnover of glycogen and its naturally wider linewidth, 32 spectra 
were summed for accurate quantification of its 13C signal area at 
100.5 ppm.
Figure 3 shows typical curves of glucose concentration and 13C 
labeling in plasma, as well as brain [1‐13C]glucose, in one GK and 
one Wistar rat during the 13C MRS experiment. Glucose transport 
and consumption rates were estimated from these curves. Tmax was 
1.14 ± 0.22 and 0.78 ± 0.30 µmol/g/min (p = 0.031), Kt was 0.9 ± 1.0 
and 1.4 ± 2.1 mM (p = 0.625), and CMRglc was 0.65 ± 0.13 and 
0.46 ± 0.21 µmol/g/min (p = 0.062) in Wistar and GK rats, respec‐
tively. Interestingly, this resulted in similar ratio of Tmax to CMRglc: 
1.8 ± 0.4 in controls and 1.8 ± 0.8 in GK rats (p = 0.763), suggesting 
that the relation of brain to plasma glucose levels is not changed in 
diabetic GK rats.
Labeling of brain glycogen from [1‐13C]glucose was slower 
in GK than Wistar rats (Figure 4). The rate of glycogen synthesis 
(Vglyc), which was two orders of magnitude slower than CMRglc, was 
0.004 ± 0.002 and 0.008 ± 0.004 µmol/g/min in GK and Wistar rats, 
respectively (p = 0.028). In µmol/g/h, Vglyc was 0.25 ± 0.12 in GK 
rats and 0.48 ± 0.22 in controls. Taking in account brain glycogen 
concentration, glycogen turnover time τ was 26.6 ± 13.6 hr in GK 
rats and 14.4 ± 4.2 hr in Wistar rats (p = 0.041).
3.2 | Regional glycogen labeling
We further investigated the regional distribution of glycogen in the 
brain (Figure 5a). Diabetes affected brain glycogen concentration 
(F1,48 = 13.4, p = 0.001) and there was also a significant effect of 
brain region (F3,48 = 7.1, p < 0.001), but no interaction (F3,48 = 2.5, 
p = 0.062). Posttests revealed reduced glycogen in the striatum of 
GK rats compared to controls (−44%, p = 0.001). Diabetes also af‐
fected brain glucose concentration (F1,48 = 11.8, p = 0.001), and 
there was a brain region effect (F3,48 = 3.5, p = 0.020; interaction 
F3,48 = 1.7, p = 0.178). Upon post hoc testing, the reduction of 
F I G U R E  1   Plasma glucose concentration (a) and FE (b) in Wistar (n = 6) and GK (n = 8) rats during [1‐13C]glucose infusion. The trace and 
shaded area are the mean and SD, respectively
??????????????????????? ? ??? ??? ??????????????????????????????????????????????? ? ??? ??? ???????????? ??? ??? ??? ?????? ??? ??? ????? ??????? ?? ???????(a) (b)
F I G U R E  2    Typical 13C spectra acquired in vivo in the rat brain 
upon infusion of [1‐13C]glucose. Each spectrum is the accumulation 
of 4,096 scans (68 min). Lorentzian line broadening of 10 Hz was 
applied prior to Fourier transformation. The inset rat brain image 
shows the typical location of the VOI used for 13C MRS
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glucose concentration was significant in the cortex (−37% vs. Wistar, 
p = 0.047) and striatum (−37% vs. Wistar, p = 0.010).
Whole‐brain glycogen turnover was reduced in the brain of 
GK rats, compared to controls, which resulted in reduced brain 
glycogen enrichment at the end of the [1‐13C]glucose infusion. 
In turn, when investigating 13C labeling in extracts from specific 
brain areas by GC‐MS, we observed significant effects of diabetes 
(F1,48 = 50.4, p < 0.001) and brain region (F3,48 = 17.0, p < 0.001), 
but no interaction (F3,48 < 0.1, p = 0.979). In particular, there was 
a reduction of glycogen 13C enrichment of 33% in the hypothala‐
mus (p = 0.002), 29% in the hippocampus (p = 0.002), 25% in the 
striatum (p = 0.002), and 24% in the cortex (p = 0.002) of GK rats, 
relative to Wistar rats (Figure 5b). Since 13C labeling of glucose in 
these brain areas was about 21%–22% lower in GK than controls 
(p < 0.001 for all posttests), we infer that the diabetes‐induced re‐
duction of glycogen labeling was most prominent in the hypothala‐
mus and hippocampus.
3.3 | GLUT1 and glycogen metabolizing enzymes
Since glucose uptake from the blood stream is primarily mediated 
by GLUT1, the density of the glucose carrier GLUT 1 was analyzed 
by Western blot (Figure 6a), which detected the two glycosylation 
forms that are specifically present in endothelial cells (55 kDa) and 
brain parenchyma (45 kDa) (Simpson, Carruthers, & Vannucci, 2007). 
The immunoreactivity of GLUT1 in the striatum and cortex was simi‐
lar between GK and Wistar rats. In the hypothalamus, there was a 
significant T2D‐induced reduction of the 55 kDa (−41%, p = 0.041) 
form of GLUT1. GK rats had significantly lower 45 kDa GLUT1 im‐
munoreactivity in the hippocampus, when compared to controls 
(−19%, p = 0.030).
Glycogen concentration is directly dependent on the activities 
of glycogen synthase and glycogen phosphorylase. The density of 
both muscle and brain isoforms of glycogen phosphorylase was sim‐
ilar in GK rats and controls (Figure 6b,c). Glycogen synthase levels 
were affected by diabetes. Namely, we observed a 21% reduction 
in the density of glycogen synthase in the hippocampus of GK rats, 
relative to controls (p = 0.015; Figure 6d). Moreover, we measured 
the density of phospho‐glycogen synthase at the phosphorylation 
sites Ser460 and Ser641. The level of phospho‐glycogen synthase 
in the cortex was significantly higher in GK than Wistar rats (+57%, 
p = 0.027, Figure 6e). The rate of glycogen synthase phosphorylation 
was higher in the cortex (+47%, p = 0.042) and hippocampus (+69%, 
p = 0.007), but lower in the striatum (−38%, p = 0.042) of GK rats, 
when compared to controls.
F I G U R E  3   Typical fit of brain [1‐13C]glucose time courses 
([1‐13C]Glcbrain) as function of plasma glucose (Glcplasma) 
concentration (a) and 13C labeled Glcplasma (b). In the particular 
cases of this figure, best fit in panel c resulted in Tmax was 1.37 and 
0.92 µmol/g/min and CMRglc was 0.77 and 0.65 µmol/g/min for 
Wistar and GK rats, respectively
(a)
(b)
(c)
F I G U R E  4   Typical brain glycogen labeling curves (a), mean Vgly (b) and τ (c) in the brain of Wistar and GK rats. *p < 0.05 for GK (n = 8) 
versus Wistar (n = 6). Panels b and c are Tukey plots with mean value indicated by +
?? ???????? ??? ??? ??????????????? ???????? ?????? ?????????????? ? ?????? ????????? ?(b)(a) (c)
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4  | DISCUSSION
The present results confirm previous findings that brain glucose uti‐
lization is reduced in the brain of diabetic GK rats, relative to con‐
trols (Girault et al., 2019), and provide evidence for impaired brain 
glycogen metabolism that might contribute to the learning and mem‐
ory deficits in this diabetes model (Duarte et al., 2019; Li et al., 2013).
4.1 | Brain glucose utilization
The brain requires continuous glucose supply to sustain metabolic 
demands of neuronal activity. By analyzing the labeling of brain 
[1‐13C]glucose over time, we determined a 31% reduction in Tmax, the 
apparent maximum glucose transport rate, which is in accordance 
with reduced density of glucose carriers at the blood‐brain‐barrier 
(BBB). We further observed a tendency for reduced CMRglc (−29%) 
in GK rats relative to controls, which suggests a global glucose 
hypo‐metabolism. A reduction in both CMRglc and Tmax resulted in 
identical ratio of Tmax to CMRglc, indicating that brain glucose lev‐
els are similar in GK and Wistar rats at any given glycemia (Duarte 
et al., 2019; Girault et al., 2019). Nevertheless, since GK rats dis‐
play sustained hyperglycemia, their brains are exposed to excessive 
glucose levels when compared to normoglycemic rats, which may 
trigger a plethora of deleterious effects leading to neurodegenera‐
tion, namely through oxidative stress and non‐enzymatic glycation 
of macromolecules (Duarte, 2015).
In GK rats, GLUT1 density was found reduced in total protein 
extracts of the hippocampus and hypothalamus, regions crucial 
for learning and memory and for regulation of glucose homeosta‐
sis, respectively. Interestingly, brain glucose content was particu‐
larly reduced in the cortex and striatum of GK rats compared to 
controls, while GLUT1 density was not modified by T2D in these 
brain areas. This clearly indicates that although total levels of 
GLUT1 may represent the availability of carriers to mediate glu‐
cose transport, they are not indicative of BBB transport capacity. 
Accordingly, cerebral glucose utilization was found reduced in the 
brain of db/db mice, a model of T2D, relative to controls (Garris, 
Williams, Coleman, & Morgan, 1984; Vannucci, Gibbs, & Simpson, 
1997). However, Vannucci et al. reported no changes in the density 
of the glucose carriers GLUT1, widely expressed in the brain and 
the main glucose carrier at the BBB, and GLUT3, mainly located in 
neuronal membranes, in brain preparations obtained from db/db 
mice, when compared to wild‐type mice (Vannucci et al., 1997). 
In contrast, a recent study reported lower levels of both GLUT1 
and GLUT3 in whole‐brain homogenates prepared from mice ex‐
posed to a diet rich in fat and sugar for 3 months, which develop 
an insulin‐resistant phenotype, relative to mice fed a regular chow 
(Kothari et al., 2017). Altogether, these observations lead us to 
speculate that reduced glucose transport and utilization is caused 
by changes in metabolic regulation according to cellular needs 
and adaptations to a diabetic and neurodegenerative state rather 
than reduced glucose carrier concentrations. Nevertheless, defi‐
ciency of GLUT1 results in reduced brain glucose uptake, and was 
suggested to contribute to cerebral microvascular degeneration, 
impaired blood flow, reduced amyloid β (Aβ) peptide clearance, 
diminished neuronal activity, neurodegeneration, and behavioral 
deficits in an AD mouse model that overexpresses the Aβ precur‐
sor protein (Winkler et al., 2015). In line with this, depression of 
brain glucose metabolism is an early feature of AD (Duarte, 2015; 
Zilberter & Zilberter, 2017), demonstrated for example by reduced 
density of GLUT1 and GLUT3 in the hippocampus, caudate nu‐
cleus, and neocortex (Simpson, Chundu, Davies‐Hill, Honer, & 
Davies, 1994), reduced binding of the non‐competitive inhibitor 
of glucose carriers [3H]cytochalasin B to neocortical and hippo‐
campal tissue and microvessels (Kalaria & Harik, 1989), or reduced 
cortical glucose transport and CMRglc (Jagust et al., 1991).
F I G U R E  5    Regional distribution of glucose and glycogen concentrations (a) and 13C fractional enrichment (b) in the brain of GK (n = 8) 
and Wistar (n = 6) rats. Results are shown in Tukey plots with mean value indicated by + and outliers by symbols (open circles for Wistar and 
filled triangles for GK rats). *p < 0.05, **p < 0.01, ***p < 0.001 for GK versus Wistar in Holm‐Sidak's posttests after significant 2‐way ANOVA
??????????????? ??????? ?????????????? ??? ?????????????????
??? ???? ???????????? ?????? ???? ?? ?? ??????? ? ???????
?? ???
?????????????????? ??????????? ???????? ?????????????????? ??????????? ????????
(a) (b)
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Insulin was suggested to modulate astrocytic glucose metab‐
olism by acting in concert with the insulin‐like growth factor type 
1 (IGF‐1), namely via a mitogen‐activated protein kinase/protein 
kinase D pathway that controls maintenance of GLUT1 at the cell 
membrane (Fernandez et al., 2017). While insulin is the main regula‐
tor of peripheral glucose homeostasis, it is traditionally considered 
to not directly modulate global brain glucose uptake and utilization. 
Therefore, the extent of this insulin‐IGF‐1 interaction within glucose 
transport regulation remains unclear, although it might be of impor‐
tance in neurodegenerative disorders that involve insulin resistance. 
For example, while hyperinsulinemia within the normal physiologic 
range does not impact glucose transport or CMRglc (Hasselbalch et 
al., 1999), insulin was shown to stimulate brain glucose metabolism 
in subjects with impaired glucose tolerance (Hirvonen et al., 2011). 
Moreover, insulin has a major role in multiple brain processes that 
require energy and thus insulin can indirectly modulate brain glucose 
homeostasis (reviewed in Duarte, 2015).
4.2 | Brain glycogen metabolism
Assuming that the whole glycogen pool is being metabolized at a rate 
of 0.48 µmol/g/h, we estimated that about 14 hr would be necessary 
for the brain glycogen pool to turnover in Wistar rats. Previous 13C‐
MRS studies in rats under light α‐chloralose anesthesia, have esti‐
mated similar (Choi, Tkác, Ugurbil, & Gruetter, 1999) or slightly faster 
(0.7 µmol/g/h, van Heeswijk, Morgenthaler, Xin, & Gruetter, 2010) 
glycogen turnover rates. The discrepancy on the measured turnover 
rates in our study and these previous publications could be caused 
by either the deepness of anesthesia that modulates brain activity 
and metabolism (Sonnay, Gruetter, & Duarte, 2017), or the brain 
F I G U R E  6   Western blot analysis of GLUT1 detected the highly glycosylated (top band, 55 kDa) and less glycosylated (lower band, 
45 kDa) isoforms (a), which are present in endothelial cells and brain parenchyma, respectively. The relation between the normalized 
immunoreactivity of both GLUT1 forms is plotted together with the line of equality. Immunoreactivity of brain glycogen phosphorylase (b), 
muscle glycogen phosphorylase (c), and glycogen synthase (d) was detected at 97, 94, and 84 kDa, respectively. Panel e shows phospho‐
glycogen synthase immunoreactivity (84 kDa) and the ratio of phospho‐ to total glycogen synthase (GS). SDS‐PAGE gels were loaded with 
40 µg of protein for analysis of GLUT1, and with 100 µg for the remaining proteins. Data points are shown in symbols (open circles for 
Wistar, and filled triangles for GK rats), and bars indicate the mean value of n = 2–3, as depicted in the respective immunoreactivity pictures. 
The cortex from one GK rat was lost during sample preparation, thus only n = 2 was available for SDS‐PAGE. *p < 0.05 from Student t test 
comparisons between GK and Wistar
(a)
(b) (c)
(d) (e)
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levels of insulin that might stimulate glycogen synthesis (Fernandez 
et al., 2017; Muhič et al., 2015). Accordingly, administration of insu‐
lin to anaesthetized rats was previously reported to increase brain 
glycogen levels (Morgenthaler et al., 2006). In fact, circulating levels 
of insulin in the present study under isoflurane were much lower 
than those in similar experimental conditions but under α‐chloralose 
anesthesia (Girault et al., 2019).
The 13C incorporation from glucose into glycogen was conspicu‐
ously hampered in GK rats, relative to non‐diabetic Wistar rats under 
identical experimental conditions. In the whole brain, glycogen syn‐
thesis rate was reduced by 48% in GK rats, relative to controls. This 
was further supported by the fact that the phosphorylation rate of 
glycogen synthase was increased in the cortex and hippocampus of 
GK rats, relative to controls, in line with reduced activity. However, 
whole‐brain glycogen content was found similar. Therefore, we es‐
timated brain glycogen turnover time to be increased by 85% in di‐
abetic rats.
While total brain glycogen content in GK rats at the end of the 
hyperglycemic clamp was similar to that of Wistar rats, GK rats 
had lower glycogen concentration in the striatum than controls. 
Another rat model of T2D, the Zucker diabetic fatty rat, displayed 
lower brain glycogen content than lean littermates, but higher than 
control Sprague‐Dawley rats (Sickmann et al., 2010). Then, we 
found that glycogen labeling from glucose was reduced in the hip‐
pocampus and the hypothalamus. Furthermore, higher phosphor‐
ylation rate of glycogen synthase in GK rats than controls is in line 
with reduced brain glycogen synthase activity, namely in the cor‐
tex and hippocampus. The antibody anti‐phospho‐glycogen syn‐
thase used in this study targets two serine phosphorylation sites, 
the Ser640 and Ser641, in liver and brain isoforms (according to 
supplier). This site is phosphorylated by the serine/threonine pro‐
tein kinase glycogen synthase kinase 3 (GSK‐3), as well as Ser644 
and Ser648, resulting in a potent inactivating effect (Roach, 1990; 
Skurat & Roach, 1995).
The hippocampus of GK rats showed prominently reduced lev‐
els of glycogen synthase. Notably, mice lacking glycogen synthase 
in the brain display impaired acquisition of an associative learning 
task, as well as impaired hippocampal long‐term potentiation (Duran 
et al., 2013). In contrast to glycogen synthase, we found no changes 
in levels of glycogen phosphorylase muscle and brain isoforms. The 
liver isoform was not investigated due to its vestigial presence in the 
adult brain (Pfeiffer‐Guglielmi, Bröer, Bröer, & Hamprecht, 2000). 
Although it would be of interest to determine the phosphorylation 
rate of glycogen phosphorylase in the present study, to our knowl‐
edge there are no good antibodies against its phosphorylation sites. 
Nevertheless, phosphorylation is not the main regulatory mecha‐
nism of the enzyme activity. Glycogen phosphorylase is regulated 
allosterically by AMP and activated by phosphorylation by the phos‐
phorylase kinase, and the brain isoform in astrocytes responds more 
strongly to AMP than does the muscle isoform (Bak et al., 2018; 
Müller, Pedersen, Walls, Waagepetersen, & Bak, 2015). In sum, total 
protein level alterations (or their absence) may not directly translate 
into equivalent changes of enzyme activity.
Altogether, our findings suggest hampered dynamics of the 
brain glycogen pool, at least in the diabetic GK rat model. This has 
likely an impact on brain activity that depends on glycogen as an 
energy source, such as memory formation (Gibbs et al., 2007; Suzuki 
et al., 2011). Impaired learning and memory capabilities in GK rats 
have been associated with the degree of insulin resistance (Li et al., 
2013), and it was also proposed that hippocampal insulin resistance 
impairs spatial learning and synaptic plasticity (Grillo et al., 2015) 
and is associated to astrogliosis and neuroinflammation (Calvo‐
Ochoa, Hernández‐Ortega, Ferrera, Morimoto, & Arias, 2014). 
Thus, we propose that hampered glycogen utilization in the diabetic 
brain may provide a biochemical link between cognitive impairment 
and insulin resistance. In line with this, noradrenergic dysfunction 
has been proposed to be an important component of AD (Hertz, 
1989; Marien, Colpaert, & Rosenquist, 2004; Weinshenker, 2008). 
Noradrenaline both modulates memory (reviewed in Alberini, 
Cruz, Descalzi, Bessières, & Gao, 2018), and stimulates glycogeno‐
lysis and exerts a complex regulation of glycolysis and glycogen 
shunting in astrocytes (Walls, Heimbürger, Bouman, Schousboe, & 
Waagepetersen, 2009 and references therein). Insulin and diabetes 
were suggested to modify brain noradrenaline metabolism and lev‐
els (Kwok & Juorio, 1988; Lacković, Salković, Kuci, & Relja, 1990; 
Trulson & Himmel, 1985), but the role of the noradrenergic system 
on the control of glycogen metabolism in the diabetic brain remains 
to be investigated.
4.3 | Limitations
In accordance with the insulin resistance state, when GK rats were 
infused a 13C‐enriched glucose solution, a strong dilution of its FE 
was observed in the plasma, when comparing with non‐diabetic 
Wistar rats. This finding is in agreement with increased endogenous 
glucose production from gluconeogenesis in GK relative to Wistar 
rats (Sena, Barosa, Nunesa, Seiça, & Jones, 2007), which accounts 
for the unlabeled glucose in the blood stream. Another difference 
between the experimental groups is the younger age of the Wistar 
rats (4–6 months old) relative to GK rats (all 6 months old). This dif‐
ference was because age‐matched controls are often too large to 
fit in the fixation system used for MRS in this study. Nevertheless, 
energy metabolism differences are not expected to occur in the rat 
brain within this age range (Dienel, 2012).
Lower isoflurane levels were needed for anesthesia of GK rats, 
compared to controls, and the doses of isoflurane within this range 
show sigmoidal responses in animal immobility tests (Saab et al., 
2010). In line with this, metabolic assessments under different an‐
esthesia doses (29% less in GK than Wistar rats) may also bias our 
metabolic assessments. Any anesthesia reduces glucose uptake 
and consumption relative to the awake state, and we have shown 
that Tmax and CMRglc are similar under isoflurane and light α‐chlo‐
ralose anesthesia (Duarte & Gruetter, 2012). Therefore, the lighter 
anesthesia in GK than Wistar rats might result in higher metabolic 
activity in GK than Wistar rats, and thus lead to an underestima‐
tion of T2D‐induced effects on brain glycogen metabolism. On 
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the contrary, it is known that isoflurane inhibits the mitochondrial 
electron transport chain in a dose‐dependent manner (Hanley, Ray, 
Brandt, & Daut, 2002; Zimin et al., 2018). This results in increased 
lactate in the brain, and also in circulation. Indeed, circulating lac‐
tate was similar at baseline, but lower in GK than Wistar rats during 
glucose infusion (Table 1). Accordingly, isoflurane anesthesia could 
eventually exacerbate glucose utilization at glycolytic level to fulfil 
eventual needs of ATP. Being possible that these isoflurane doses 
have effects on some assessed parameters but not others, future 
studies on GK rats should consider a dose‐response curve for isoflu‐
rane and the determination of minimum alveolar concentration value 
in these strains.
With 13C MRS in vivo, we measured brain glycogen turnover 
using [1‐13C]glucose as a precursor, which was infused for at least 
8 hr. Our measurements assume that glycogen content doesn't 
change during the experiments and that, therefore, the appearance 
of [1‐13C]glycogen reflects turnover, i.e., replacement of glucosyl 
units in glycogen without net synthesis. Although glycogen in the 
brain of awake rats does not change with hyperglycemia (Duarte et 
al., 2017), glycogen accumulation occurs upon glucose infusion under 
α‐chloralose anesthesia, likely mediated by insulin (Morgenthaler et 
al., 2006). Glucose‐stimulated insulin secretion in rats under isoflu‐
rane anesthesia resulted in circulating insulin concentration (Table 1) 
that is one order of magnitude smaller than that under α‐chloralose 
anesthesia (Girault et al., 2019). One might thus speculate that brain 
glycogen accumulation is much smaller than that reported previously 
(Morgenthaler et al., 2006). Moreover, circulating insulin was similar 
between GK rats and controls, as well as brain glycogen levels after 
the hyperglycemic clamp of our experimental protocol. Therefore, 
the conclusion that glycogen metabolism is slower in GK than Wistar 
rats remains valid, despite the possibility of net glycogen synthesis 
to occur.
It should also be noted the small sample sizes in this study, namely 
n = 2–3 for protein determination by Western blot, and n = 6–8 for 
13C tracing experiments. Despite the limited number of rats used, 
altogether the experiments of our study point in the direction of 
T2D‐associated alterations of glycogen metabolism.
Metabolism of glucose and glycogen is linked to glutamatergic 
neurotransmission (Gibbs et al., 2007; Sickmann et al., 2009; Sonnay 
et al., 2017). However, the present results are not sufficient to de‐
termine whether brain hypo‐metabolism and reduced glycogen turn‐
over are cause or consequence of the previously reported reduced 
glutamate‐glutamine cycle rate in the brain of GK rats (Girault et al., 
2019).
DECL AR ATION OF TR ANSPARENC Y
The authors, reviewers and editors affirm that in accordance to the 
policies set by the Journal of Neuroscience Research, this manu‐
script presents an accurate and transparent account of the study 
being reported and that all critical details describing the methods 
and results are present.
ACKNOWLEDG MENTS
The authors are grateful to Jordi Duran (Institute for Research in 
Biomedicine, Barcelona) for advice on Western blotting experiments 
for glycogen‐metabolizing enzymes.
CONFLIC T OF INTERE S T
The authors have no conflicts of interest to declare.
AUTHOR CONTRIBUTIONS
Methodology, J.M.N.D.; Formal Analysis, A.F.S., S.S.N., J.D.N., A.G.S. 
and J.M.N.D.; Writing – Original Draft, A.F.S. and J.M.N.D. All authors 
revised and edited the manuscript.
DATA AVAIL ABILIT Y
The data that support the findings of this study are available from 
the corresponding author upon reasonable request.
ORCID
Helle S. Waagepetersen  https://orcid.org/0000‐0003‐4583‐8379 
João M. N. Duarte  https://orcid.org/0000‐0001‐5984‐1574 
R E FE R E N C E S
Alberini, C. M., Cruz, E., Descalzi, G., Bessières, B., & Gao, V. (2018). 
Astrocyte glycogen and lactate: New insights into learning and mem‐
ory mechanisms. Glia, 66(6), 1244–1262.
Bak, L. K., Walls, A. B., Schousboe, A., & Waagepetersen, H. S. (2018). 
Astrocytic glycogen metabolism in the healthy and diseased brain. 
Journal of Biological Chemistry, 293(19), 7108–7116.
Baker, L. D., Cross, D., Minoshima, S., Belongia, D., Watson, G. S., & 
Craft, S. (2011). Insulin resistance is associates with Alzheimer‐like 
reductions in regional cerebral glucose metabolism for cognitively 
impaired normal adults with pre‐diabetes or early type 2 diabetes. 
Archives of Neurology, 68, 51–57.
Baumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, 
H. (2015). Summary of the evidence on modifiable risk factors for 
cognitive decline and dementia: A population‐based perspective. 
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 
11(6), 718–726.
Biemann, K. (1962). Mass spectrometry. In Biemann K., (ed.), Organic 
chemistry applications (pp 223–227). New York, NY: McGraw.
Calì, C., Baghabra, J., Boges, D. J., Holst, G. R., Kreshuk, A., Hamprecht, 
F. A., … Magistretti, P. J. (2016). Three‐dimensional immersive virtual 
reality for studying cellular compartments in 3D models from EM 
preparations of neural tissues. The Journal of Comparative Neurology, 
524(1), 23–38.
Calvo‐Ochoa, E., Hernández‐Ortega, K., Ferrera, P., Morimoto, S., & 
Arias, C. (2014). Short‐term high‐fat‐and‐fructose feeding produces 
insulin signaling alterations accompanied by neurite and synaptic re‐
duction and astroglial activation in the rat hippocampus. Journal of 
Cerebral Blood Flow and Metabolism, 34(6), 1001–1008.
Candeias, E., Duarte, A. I., Sebastião, I., Fernandes, M. A., Plácido, A. I., 
Carvalho, C., … Moreira, P. I. (2016). Middle‐aged diabetic females 
and males present distinct susceptibility to Alzheimer disease‐like 
     |  1015SOARES Et Al.
pathology. Molecular Neurobiology, 54(8), 6471–6489. https ://doi.
org/10.1007/s12035‐016‐0155‐1
Cataldo, A. M., & Broadwell, R. D. (1986). Cytochemical identification of 
cerebral glycogen and glucose‐6‐phosphatase activity under normal 
and experimental conditions: I. Neurons and glia. Journal of Electron 
Microscopy Technique, 3, 413–437.
Choi, I. Y., Seaquist, E. R., & Gruetter, R. (2003). Effect of hypoglyce‐
mia on brain glycogen metabolism in vivo. Journal of Neuroscience 
Research, 72, 25–32.
Choi, I. Y., Tkác, I., Ugurbil, K., & Gruetter, R. (1999). Noninvasive mea‐
surements of [1‐13C]glycogen concentrations and metabolism in rat 
brain in vivo. Journal of Neurochemistry, 73(3), 1300–1308.
Cruz, N. F., & Dienel, G. A. (2002). High glycogen levels in brains of rats 
with minimal environmental stimuli: Implications for metabolic con‐
tributions of working astrocytes. Journal of Cerebral Blood Flow and 
Metabolism, 22(12), 1476–1489.
Desrois, M., Sidell, R. J., Gauguier, D., Davey, C. L., Radda, G. K., & Clarke, 
K. (2004). Gender differences in hypertrophy, insulin resistance 
and ischemic injury in the aging type 2 diabetic rat heart. Journal of 
Molecular and Cellular Cardiology, 37(2), 547–555.
Dienel, G. A. (2012). Fueling and imaging brain activation. ASN Neuro, 
4, 5.
Duarte, J. M. N. (2015). Metabolic alterations associated to brain dys‐
function in diabetes. Aging and Disease, 6(5), 304–321.
Duarte, J. M. N., Carvalho, R. A., Cunha, R. A., & Gruetter, R. (2009). 
Caffeine consumption attenuates neurochemical modifications in 
the hippocampus of streptozotocin‐induced diabetic rats. Journal of 
Neurochemistry, 111, 368–379.
Duarte, J. M. N., Cunha, R. A., & Carvalho, R. A. (2007). Different metab‐
olism of glutamatergic and GABAergic compartments in superfused 
hippocampal slices characterized by nuclear magnetic resonance 
spectroscopy. Neuroscience, 144(4), 1305–1313.
Duarte, J. M. N., & Gruetter, R. (2012). Characterization of cerebral 
glucose dynamics in vivo with a four‐state conformational model 
of transport at the blood‐brain barrier. Journal of Neurochemistry, 
121(3), 396–406.
Duarte, J. M. N., Lanz, B., & Gruetter, R. (2011). Compartmentalized cere‐
bral metabolism of [1,6–13C]glucose determined by in vivo 13C NMR 
spectroscopy at 14.1 T. Frontiers in Neuroenergetics, 6, 3.
Duarte, J. M. N., Morgenthaler, F. D., & Gruetter, R. (2017). Glycogen 
supercompensation in the rat brain after acute hypoglycemia is inde‐
pendent of glucose levels during recovery. Neurochemical Research, 
42(6), 1629–1635.
Duarte, J. M. N., Skoug, C., Silva, H. B., Carvalho, R. A., Gruetter, R., & 
Cunha, R. A. (2019). Impact of caffeine consumption on type 2 dia‐
betes‐induced spatial memory impairment and neurochemical alter‐
ations in the hippocampus. Frontiers in Neuroscience, 12, 1015.
Duran, J., Saez, I., Gruart, A., Guinovart, J. J., & Delgado‐García, J. M. 
(2013). Impairment in long‐term memory formation and learning‐
dependent synaptic plasticity in mice lacking glycogen synthase 
in the brain. Journal of Cerebral Blood Flow and Metabolism, 33(4), 
550–556.
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.‐G. (2009). Statistical power 
analyses using G*Power 3.1: Tests for correlation and regression 
analyses. Behavior Research Methods, 41, 1149–1160.
Fernandez, A. M., Hernandez‐Garzón, E., Perez‐Domper, P., Perez‐
Alvarez, A., Mederos, S., Matsui, T., … Torres Aleman, I. (2017). 
Insulin regulates astrocytic glucose handling through cooperation 
with IGF‐I. Diabetes, 66(1), 64–74.
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, 
D., … Panza, F. (2010). Metabolic‐cognitive syndrome: A cross‐talk 
between metabolic syndrome and Alzheimer's disease. Ageing 
Research Reviews, 9(4), 399–417.
Garris, D. R., Williams, S. K., Coleman, D. L., & Morgan, C. R. (1984). 
Glucose utilization by the mouse brain: Influence of age and diabetes. 
Brain Research, 317(2), 141–146.
Genda, E. N., Jackson, J. G., Sheldon, A. L., Locke, S. F., Greco, T. M., 
O'Donnell, J. C., … Robinson, M. B. (2011). Co‐compartmental‐
ization of the astroglial glutamate transporter, GLT‐1, with glyco‐
lytic enzymes and mitochondria. Journal of Neuroscience, 31(50), 
18275–18288.
Gibbs, M. E., Anderson, D. G., & Hertz, L. (2006). Inhibition of glycogeno‐
lysis in astrocytes interrupts memory consolidation in young chick‐
ens. Glia, 54(3), 214–222.
Gibbs, M. E., Lloyd, H. G., Santa, T., & Hertz, L. (2007). Glycogen is a 
preferred glutamate precursor during learning in 1‐day‐old chick: 
Biochemical and behavioral evidence. Journal of Neuroscience 
Research, 85(15), 3326–3333.
Girault, F. M., Sonnay, S., Gruetter, R., & Duarte, J. M. N. (2019). 
Alterations of brain energy metabolism in type 2 diabetic Goto‐
Kakizaki rats measured in vivo by 13C magnetic resonance spec‐
troscopy. Neurotoxicity Research. In press. https ://doi.org/10.1007/
s12640‐017‐9821‐y
Goto, Y., Kakizaki, M., & Masaki, N. (1976). Production of spontaneous 
diabetic rats by repetition of selective breeding. Tohoku Journal of 
Experimental Medicine, 119(1), 85–90.
Grillo, C. A., Piroli, G. G., Lawrence, R. C., Wrighten, S. A., Green, A. J., 
Wilson, S. P., … Reagan, L. P. (2015). Hippocampal insulin resistance 
impairs spatial learning and synaptic plasticity. Diabetes, 64(11), 
3927–3936.
Hanley, P. J., Ray, J., Brandt, U., & Daut, J. (2002). Halothane, isoflurane 
and sevoflurane inhibit NADH:Ubiquinone oxidoreductase (complex 
I) of cardiac mitochondria. Journal of Physiology, 544(3), 687–693.
Hasselbalch, S. G., Knudsen, G. M., Videbaek, C., Pinborg, L. H., Schmidt, 
J. F., Holm, S., & Paulson, O. B. (1999). No effect of insulin on glucose 
blood‐brain barrier transport and cerebral metabolism in humans. 
Diabetes, 48(10), 1915–1921.
Hertz, L. (1989). Is Alzheimer's disease an anterograde degeneration, 
originating in the brainstem, and disrupting metabolic and functional 
interactions between neurons and glial cells? Brain Research. Brain 
Research Reviews, 14(4), 335–353.
Herzog, R. I., Chan, O., Yu, S., Dziura, J., McNay, E. C., & Sherwin, R. S. 
(2008). Effect of acute and recurrent hypoglycemia on changes in 
brain glycogen concentration. Endocrinology, 149, 1499–1504.
Hirvonen, J., Virtanen, K. A., Nummenmaa, L., Hannukainen, J. C., 
Honka, M. J., Bucci, M., … Nuutila, P. (2011). Effects of insulin on 
brain glucose metabolism in impaired glucose tolerance. Diabetes, 
60(2), 443–447.
Holman, G. D., Kozka, I. J., Clark, A. E., Flower, C. J., Saltis, J., Habberfield, 
A. D., … Cushman, S. W. (1990). Cell surface labeling of glucose 
transporter isoform GLUT4 by bis‐mannose photolabel. Correlation 
with stimulation of glucose transport in rat adipose cells by in‐
sulin and phorbol ester. Journal of Biological Chemistry, 265(30), 
18172–18179.
Jackson, S. J., Waterhouse, J. S., & Bluck, L. J. (2007). A single glucose 
derivative suitable for gas chromatography/mass spectrometry and 
gas chromatography/combustion/isotope ratio mass spectrometry. 
Rapid Communications in Mass Spectrometry, 21(18), 3123–3128.
Jagust, W. J., Seab, J. P., Huesman, R. H., Valk, P. E., Mathis, C. A., Reed, 
B. R., … Budinger, T. F. (1991). Diminished glucose transport in 
Alzheimer's disease: Dynamic PET studies. Journal of Cerebral Blood 
Flow and Metabolism, 11(2), 323–330.
Kalaria, R. N., & Harik, S. I. (1989). Reduced glucose transporter at the 
blood‐brain barrier and in cerebral cortex in Alzheimer disease. 
Journal of Neurochemistry, 53(4), 1083–1088.
Koizumi, J., & Shiraishi, H. (1970). Ultrastructural appearance of glycogen 
in the hypothalamus of the rabbit following chlorpromazine adminis‐
tration. Experimental Brain Research, 10(3), 276–282.
Kong, J., Shepel, P. N., Holden, C. P., Mackiewicz, M., Pack, A. I., & Geiger, 
J. D. (2002). Brain glycogen decreases with increased periods of 
wakefulness: Implications for homeostatic drive to sleep. Journal of 
Neuroscience, 22(13), 5581–5587.
1016  |     SOARES Et Al.
Kothari, V., Luo, Y., Tornabene, T., O'Neill, A. M., Greene, M. W., Geetha, 
T., & Babu, J. R. (2017). High fat diet induces brain insulin resistance 
and cognitive impairment in mice. Biochimica et Biophysica Acta, 
1863(2), 499–508.
Kwok, R. P., & Juorio, A. V. (1988). Effects of insulin on rat brain nor‐
adrenaline. Neurochemical Research, 13(9), 887–892.
Lacković, Z., Salković, M., Kuci, Z., & Relja, M. (1990). Effect of long‐last‐
ing diabetes mellitus on rat and human brain monoamines. Journal of 
Neurochemistry, 54(1), 143–147.
Li, X. H., Xin, X., Wang, Y., Wu, J. Z., Jin, Z. D., Ma, L. N., … Jin, M. W. 
(2013). Pentamethylquercetin protects against diabetes‐related cog‐
nitive deficits in diabetic Goto‐Kakizaki rats. Journal of Alzheimer's 
Disease, 34(3), 755–767.
Marien, M. R., Colpaert, F. C., & Rosenquist, A. C. (2004). Noradrenergic 
mechanisms in neurodegenerative diseases: A theory. Brain Research. 
Brain Research Reviews, 45(1), 38–78.
Morgenthaler, F. D., Koski, D. M., Kraftsik, R., Henry, P. G., & Gruetter, 
R. (2006). Biochemical quantification of total brain glycogen con‐
centration in rats under different glycemic states. Neurochemistry 
International, 48, 616–622.
Morgenthaler, F. D., Lanz, B. R., Petit, J. M., Frenkel, H., Magistretti, P. 
J., & Gruetter, R. (2009). Alteration of brain glycogen turnover in the 
conscious rat after 5h of prolonged wakefulness. Neurochemistry 
International, 55(1–3), 45–51.
Muhič, M., Vardjan, N., Chowdhury, H. H., Zorec, R., & Kreft, M. (2015). 
Insulin and insulin‐like growth factor 1 (IGF‐1) modulate cytoplas‐
mic glucose and glycogen levels but not glucose transport across 
the membrane in astrocytes. Journal of Biological Chemistry, 290(17), 
11167–11176.
Müller, M. S., Pedersen, S. E., Walls, A. B., Waagepetersen, H. S., & Bak, 
L. K. (2015). Isoform‐selective regulation of glycogen phosphorylase 
by energy deprivation and phosphorylation in astrocytes. Glia, 63(1), 
154–162.
Nelson, S. R., Schulz, D. W., Passonneau, J. V., & Lowry, O. H. (1968). 
Control of glycogen levels in brain. Journal of Neurochemistry, 15, 
1271–1279.
Newman, L. A., Korol, D. L., & Gold, P. E. (2011). Lactate produced by gly‐
cogenolysis in astrocytes regulates memory processing. PLoS ONE, 
6(12), e28427.
Oe, Y., Baba, O., Ashida, H., Nakamura, K. C., & Hirase, H. (2016). 
Glycogen distribution in the microwave‐fixed mouse brain reveals 
heterogeneous astrocytic patterns. Glia, 64(9), 1532–1545.
Pfeiffer‐Guglielmi, B., Bröer, S., Bröer, A., & Hamprecht, B. (2000). 
Isozyme pattern of glycogen phosphorylase in the rat nervous sys‐
tem and rat astroglia‐rich primary cultures: Electrophoretic and 
polymerase chain reaction studies. Neurochemical Research, 25(11), 
1485–1491.
Phelps, C. H. (1972). Barbiturate‐induced glycogen accumulation in brain. 
An electron microscopic study. Brain Research, 39(1), 225–234.
Roach, P. J. (1990). Control of glycogen synthase by hierarchal protein 
phosphorylation. The FASEB Journal, 4(12), 2961–2968.
Saab, B. J., Maclean, A. J., Kanisek, M., Zurek, A. A., Martin, L. J., Roder, 
J. C., & Orser, B. A. (2010). Short‐term memory impairment after iso‐
flurane in mice is prevented by the α5 γ‐aminobutyric acid type A re‐
ceptor inverse agonist L‐655,708. Anesthesiology, 113(5), 1061–1071.
Sena, C. M., Barosa, C., Nunesa, E., Seiça, R., & Jones, J. G. (2007). 
Sources of endogenous glucose production in the Goto‐Kakizaki dia‐
betic rat. Diabetes & Metabolism, 33(4), 296–302.
Shulman, R. G., Hyder, F., & Rothman, D. L. (2001). Cerebral energetics 
and the glycogen shunt: Neurochemical basis of functional imaging. 
Proceedings of the National Academy of Sciences of the United States of 
America, 98(11), 6417–6422.
Sickmann, H. M., Waagepetersen, H. S., Schousboe, A., Benie, A. J., & 
Bouman, S. D. (2010). Obesity and type 2 diabetes in rats are as‐
sociated with altered brain glycogen and amino‐acid homeostasis. 
Journal of Cerebral Blood Flow and Metabolism, 30(8), 1527–1537.
Sickmann, H. M., Walls, A. B., Schousboe, A., Bouman, S. D., & 
Waagepetersen, H. S. (2009). Functional significance of brain gly‐
cogen in sustaining glutamatergic neurotransmission. Journal of 
Neurochemistry, 109(Suppl 1), 80–86.
Simpson, I. A., Carruthers, A., & Vannucci, S. J. (2007). Supply and de‐
mand in cerebral energy metabolism: The role of nutrient trans‐
porters. Journal of Cerebral Blood Flow and Metabolism, 27(11), 
1766–1791.
Simpson, I. A., Chundu, K. R., Davies‐Hill, T., Honer, W. G., & Davies, 
P. (1994). Decreased concentrations of GLUT1 and GLUT3 glucose 
transporters in the brains of patients with Alzheimer's disease. 
Annals of Neurology, 35(5), 546–551.
Sinadinos, C., Valles‐Ortega, J., Boulan, L., Solsona, E., Tevy, M. F., 
Marquez, M., … Guinovart, J. J. (2014). Neuronal glycogen synthesis 
contributes to physiological aging. Aging Cell, 13(5), 935–945.
Skurat, A. V., & Roach, P. J. (1995). Phosphorylation of sites 3a and 3b 
(Ser640 and Ser644) in the control of rabbit muscle glycogen syn‐
thase. Journal of Biological Chemistry, 270(21), 12491–12497.
Sonnay, S., Gruetter, R., & Duarte, J. M. N. (2017). How energy metab‐
olism supports cerebral function: Insights from 13C magnetic reso‐
nance studies in vivo. Frontiers in Neuroscience, 11, 288.
Spauwen, P. J., Köhler, S., Verhey, F. R., Stehouwer, C. D., & van Boxtel, 
M. P. (2013). Effects of type 2 diabetes on 12‐year cognitive change: 
Results from the Maastricht Aging Study. Diabetes Care, 36(6), 
1554–1561.
Steculorum, S. M., Solas, M., & Brüning, J. C. (2014). The paradox of neu‐
ronal insulin action and resistance in the development of aging‐asso‐
ciated diseases. Alzheimer's & Dementia: The Journal of the Alzheimer's 
Association, 10(1 Suppl), S3–11.
Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., 
Magistretti, P. J., & Alberini, C. M. (2011). Astrocyte‐neuron lactate 
transport is required for long‐term memory formation. Cell, 144(5), 
810–823. https ://doi.org/10.1016/j.cell.2011.02.018
Swanson, R. A., Morton, M. M., Sagar, S. M., & Sharp, F. R. (1992). Sensory 
stimulation induces local cerebral glycogenolysis: Demonstration by 
autoradiography. Neuroscience, 51(2), 451–461.
Swanson, R. A., Sagar, S. M., & Sharp, F. R. (1989). Regional brain gly‐
cogen stores and metabolism during complete global ischaemia. 
Neurological Research, 11(1), 24–28.
Trulson, M. E., & Himmel, C. D. (1985). Effects of insulin and streptozo‐
tocin‐induced diabetes on brain norepinephrine metabolism in rats. 
Journal of Neurochemistry, 44(6), 1873–1876.
van Heeswijk, R. B., Morgenthaler, F. D., Xin, L., & Gruetter, R. (2010). 
Quantification of brain glycogen concentration and turnover 
through localized 13C NMR of both the C1 and C6 resonances. NMR in 
Biomedicine, 23(3), 270–276.
van Heeswijk, R. B., Pilloud, Y., Morgenthaler, F. D., & Gruetter, R. (2012). 
A comparison of in vivo 13C MR brain glycogen quantification at 9.4 
and 14.1 T. Magnetic Resonance in Medicine, 67, 1523–1527.
Vannucci, S. J., Gibbs, E. M., & Simpson, I. A. (1997). Glucose utilization 
and glucose transporter proteins GLUT‐1 and GLUT‐3 in brains of 
diabetic (db/db) mice. American Journal of Physiology, 272(2 Pt 1), 
E267–E274.
Walls, A. B., Bak, L. K., Sonnewald, U., Schousboe, A., & Waagepetersen, 
H. S. (2014). Metabolic mapping of astrocytes and neurons in cul‐
ture using stable isotopes and gas chromatography‐mass spectros‐
copy (GC‐MS). In J. Hirrlinger & H. S. Waagepetersen (Eds.),Brain en-
ergy metabolism, neuromethods (vol. 90, pp. 73–105). New York, NY: 
Springer Science+Business Media.
Walls, A. B., Heimbürger, C. M., Bouman, S. D., Schousboe, A., & 
Waagepetersen, H. S. (2009). Robust glycogen shunt activity in astro‐
cytes: Effects of glutamatergic and adrenergic agents. Neuroscience, 
158(1), 284–292.
Weinshenker, D. (2008). Functional consequences of locus coeruleus de‐
generation in Alzheimer's disease. Current Alzheimer Research, 5(3), 
342–345.
     |  1017SOARES Et Al.
Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, 
D., … Zlokovic, B. V. (2015). GLUT1 reductions exacerbate Alzheimer's 
disease vasculo‐neuronal dysfunction and degeneration. Nature 
Neuroscience, 18(4), 521–530.
Xiang, Q., Zhang, J., Li, C. Y., Wang, Y., Zeng, M. J., Cai, Z. X., … Li, X. 
H. (2015). Insulin resistance‐induced hyperglycemia decreased the 
activation of Akt/CREB in hippocampus neurons: Molecular evi‐
dence for mechanism of diabetes‐induced cognitive dysfunction. 
Neuropeptides, 54, 9–15.
Zilberter, Y., & Zilberter, M. (2017). The vicious circle of hypometabolism 
in neurodegenerative diseases: Ways and mechanisms of metabolic 
correction. Journal of Neuroscience Research, 95(11), 2217–2235.
Zimin, P. I., Woods, C. B., Kayser, E. B., Ramirez, J. M., Morgan, P. G., & 
Sedensky, M. M. (2018). Isoflurane disrupts excitatory neurotrans‐
mitter dynamics via inhibition of mitochondrial complex I. British 
Journal of Anaesthesia, 120(5), 1019–1032.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section at the end of the article.
Transparent Science Questionnaire for Authors.
How to cite this article: Soares AF, Nissen JD, Garcia‐Serrano 
AM, Nussbaum SS, Waagepetersen HS, Duarte JMN. 
Glycogen metabolism is impaired in the brain of male type 2 
diabetic Goto‐Kakizaki rats. J Neuro Res. 2019;97:1004–1017.  
https ://doi.org/10.1002/jnr.24437 
